Adage Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-150,000
Closed -$11.9M – 1109
2026
Q2
$11.9M Buy
150,000
+100,000
+200% +$7.53M 0.02% 679
2026
Q1
$3.75M Sell
50,000
-90,000
-64% -$7.1M 0.01% 796
2025
Q4
$11.1M Sell
140,000
-1,175,000
-89% -$88.5M 0.02% 643
2025
Q3
$86M Sell
1,315,000
-2,485,000
-65% -$121M 0.14% 152
2025
Q2
$150M Buy
3,800,000
+2,724,400
+253% +$89.2M 0.25% 74
2025
Q1
$32.5M Buy
1,075,600
+800,600
+291% +$26.2M 0.06% 313
2024
Q4
$9.6M Sell
275,000
-225,000
-45% -$8.41M 0.02% 619
2024
Q3
$20M Sell
500,000
-300,000
-38% -$14M 0.04% 450
2024
Q2
$38.1M Sell
800,000
-200,000
-20% -$8.2M 0.07% 276
2024
Q1
$43.4M Sell
1,000,000
-385,300
-28% -$18.4M 0.08% 256
2023
Q4
$70.1M Buy
1,385,300
+318,300
+30% +$15.2M 0.15% 154
2023
Q3
$48.4M Buy
+1,067,000
New +$44M 0.11% 204

Other funds holding IONS

Adage Capital Partners's IONS Position: Q3 2026 in Review

Adage Capital Partners sold out of Ionis Pharmaceuticals (IONS) in Q3 2026, closing a stake of 150,000 shares — an estimated $11.9M sold.

Adage Capital Partners first reported a position in IONS in Q3 2023 and held it in 12 quarters. The position peaked at $150M in Q2 2025. 465 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Adage Capital Partners reported no remaining Ionis Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Adage Capital Partners sold 150,000 Ionis Pharmaceuticals shares in Q3 2026, an estimated $11.9M.
  • Adage Capital Partners first reported a position in Ionis Pharmaceuticals in Q3 2023 and held it in 12 quarters.
  • Adage Capital Partners's Ionis Pharmaceuticals position peaked at $150M in Q2 2025.
  • 465 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.